The American Journal of Medicine
Volume 123, Issue 3, Supplement , Pages S3-S11 , March 2010

Glycemic Control and Complications in Type 2 Diabetes Mellitus

  • Mark Stolar, MD

      Affiliations

    • Corresponding Author InformationRequests for reprints should be addressed to Mark Stolar, MD, Department of Clinical Medicine, Feinberg School of Medicine, Northwestern University, 676 North Saint Clair #415, Chicago, Illinois 60611

References 

  1. Centers for Disease Control and Prevention. Centers for Disease Control National Diabetes Fact Sheet. General information and national estimates on diabetes in the United States. Atlanta, GA: Centers for Disease Control and Prevention, US Dept of Health and Human Services; 2007;
  2. Cowie CC, Rust KF, Byrd-Holt DD, et al. Prevalence of diabetes and impaired fasting glucose in adults in the US population: National Health and Nutrition Examination Survey 1999–2002. Diabetes Care. 2006;29:1263–1268
  3. Nichols GA, Hillier TA, Brown JB. Progression from newly acquired impaired fasting glucose to type 2 diabetes. Diabetes Care. 2006;30:228–233
  4. de Vegt F, Dekker JM, Jager A, et al. Relation of impaired fasting and postload glucose with incident type 2 diabetes in a Dutch population: the Hoorn Study. JAMA. 2001;285:2109–2113
  5. Garber AJ, Handelsman Y, Einhorn D, et al. Diagnosis and management of prediabetes in the continuum of hyperglycemia: when do the risks of diabetes begin? (A consensus statement from the American College of Endocrinology and the American Association of Clinical Endocrinologists). Endocr Pract. 2008;14:933–946
  6. Tapp RJ, Shaw JE, Zimmet PZ, et al. Albuminuria is evident in the early stages of diabetes onset: results from the Australian Diabetes, Obesity, and Lifestyle Study (AusDiab). Am J Kidney Dis. 2004;44:792–798
  7. American Diabetes Association. Executive summary: standards of medical care in diabetes—2009. Diabetes Care. 2009;32(suppl 1):S13–S61
  8. AACE Diabetes Mellitus Clinical Practice Guidelines Task Force. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus. Endocr Pract. 2007;13(suppl 1):3–68
  9. Koro CE, Bowlin SJ, Bourgeois N, Fedder DO. Glycemic control from 1988 to 2000 among US adults diagnosed with type 2 diabetes. Diabetes Care. 2004;27:17–20
  10. Ong KL, Cheung BM, Wong LY. Prevalence, treatment, and control of diagnosed diabetes in the US National Health and Nutrition Examination Survey 1999-2004. Ann Epidemiol. 2008;18:222–229
  11. Morgan CL, Currie CJ, Peters JR. Relationship between diabetes and mortality: a population study using record linkage. Diabetes Care. 2000;23:1103–1107
  12. Haffner SM, Lehto S, Rönnemaa T, Pyörälä K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med. 1998;339:229–234
  13. Gilmer TP, O'Connor PJ, Rush WA, et al. Predictors of health care costs in adults with diabetes. Diabetes Care. 2005;28:59–64
  14. Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329:977–986
  15. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837–853
  16. Pirart J. Diabetes mellitus and its degenerative complications: a prospective study of 4,400 patients observed between 1946 and 1973. Diabetes Care. 1978;1:168–188
  17. Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000;321:405–412
  18. Skyler JS. Diabetic complications: the importance of glucose control. Endocrinol Metab Clin North Am. 1996;25:243–254
  19. Brownlee M. The pathobiology of diabetic complications: a unifying mechanism. Diabetes. 2005;54:1615–1625
  20. Heilig CW, Concepcion LA, Riser BL, Freytag SO, Zhu M, Cortes P. Overexpression of glucose transporters in rat mesangial cells cultured in a normal glucose milieu mimics the diabetic phenotype. J Clin Invest. 1995;96:1802–1814
  21. Kaiser N, Sasson S, Feener EP, et al. Differential regulation of glucose transport and transporters by glucose in vascular endothelial and smooth muscle cells. Diabetes. 1993;42:80–89
  22. Engerman RL, Kern TS, Larson ME. Nerve conduction and aldose reductase inhibition during 5 years of diabetes or galactosaemia in dogs. Diabetologia. 1994;37:141–144
  23. Pang Y, Hunton DL, Bounelis P, Marchase RB. Hyperglycemia inhibits calcium entry and hypertrophy in neonatal cardiomyocytes. Diabetes. 2002;51:3461–3467
  24. UK Prospective Diabetes Study (UKPDS) Group. UKPDS 16: overview of 6 years' therapy of type II diabetes: a progressive disease. Diabetes. 1995;44:1249–1258
  25. Ziegler D, Rathmann W, Dickhaus T, Meisinger C, Mielck A. Prevalence of polyneuropathy in pre-diabetes and diabetes is associated with abdominal obesity and macroangiopathy: the MONICA/KORA Augsburg Surveys S2 and S3. Diabetes Care. 2008;31:464–469
  26. Monnier L, Lapinski H, Colette C. Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA1C. Diabetes Care. 2003;26:881–885
  27. Krakoff J, Hanson RL, Kobes S, Knowler WC. Comparison of the effect of plasma glucose concentrations on microvascular disease between Pima Indian youths and adults. Diabetes Care. 2001;24:1023–1028
  28. Kuusisto J, Mykkänen L, Pyörälä K, Laakso M. NIDDM and its metabolic control predict coronary heart disease in elderly subjects. Diabetes. 1994;43:960–967
  29. Khaw KT, Wareham N, Luben R, et al. Glycated haemoglobin, diabetes, and mortality in men in Norfolk cohort of European Prospective Investigation of Cancer and Nutrition (EPIC-Norfolk). BMJ. 2001;322:15–18
  30. Ducimetiere P, Eschwege E, Papoz L, Richard JL, Claude JR, Rosselin G. Relationship of plasma insulin levels to the incidence of myocardial infarction and coronary heart disease mortality in a middle-aged population. Diabetologia. 1980;19:205–210
  31. Eschwege E, Richard JL, Thibult N, et al. Coronary heart disease mortality in relation with diabetes, blood glucose, and plasma insulin levels: the Paris Prospective Study, ten years later. Horm Metab Res Suppl. 1985;15:41–46
  32. Pyörälä K. Relationship of glucose tolerance and plasma insulin to the incidence of coronary heart disease: results from two population studies in Finland. Diabetes Care. 1979;2:131–141
  33. Stolar MW. Atherosclerosis in diabetes: the role of hyperinsulinemia. Metabolism. 1988;37(suppl 1):1–9
  34. Coutinho M, Gerstein HC, Wang Y, Yusuf S. The relationship between glucose and incident cardiovascular events. Diabetes Care. 1999;22:233–240
  35. Hu FB, Stampfer MJ, Haffner SM, Solomon CG, Willett WC, Manson JE. Elevated risk of cardiovascular disease prior to clinical diagnosis of type 2 diabetes. Diabetes Care. 2002;25:1129–1134
  36. Norhammar A, Tenerz A, Nilsson G, et al. Glucose metabolism in patients with acute myocardial infarction and no previous diagnosis of diabetes mellitus: a prospective study. Lancet. 2002;359:2140–2144
  37. Kosiborod M, Inzucchi SE, Krumholz HM, et al. Glucose normalization and outcomes in patients with acute myocardial infarction. Arch Intern Med. 2009;169:438–446
  38. Hillier TA, Pedula KL. Complications in young adults with early-onset type 2 diabetes: losing the relative protection of youth. Diabetes Care. 2003;26:2999–3005
  39. Hillier TA, Pedula KL. Characteristics of an adult population with newly diagnosed type 2 diabetes: the relation of obesity and age of onset. Diabetes Care. 2001;24:1522–1527
  40. Purushothaman KR, Meerarani P, Moreno PR. Inflammation and neovascularization in diabetic atherosclerosis. Indian J Exp Biol. 2007;45:93–102
  41. Monnier L, Mas E, Ginet C, et al. Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes. JAMA. 2006;295:1681–1687
  42. Purushothaman KR, Fuster V, Sirol M, et al. Diabetic plaque inflammation and neovascularization are associated with increased reparative collagen content: implication for plaque progression in diabetic atherosclerosis. Presented at the American College of Cardiology's 55th Annual Scientific Session i2 Summit 2006; March 11–14, 2006; Atlanta, GA. J Am Coll Cardiol. 2006;47(suppl A):295A;Abstract 912-193
  43. Stettler C, Allemann S, Juni P, et al. Glycemic control and macrovascular disease in types 1 and 2 diabetes mellitus: meta-analysis of randomized trials. Am Heart J. 2006;152:27–38
  44. Esposito K, Giugliano D, Nappo F, Marfella R Campanian Postprandial Hyperglycemia Study Group. Regression of carotid atherosclerosis by control of postprandial hyperglycemia in type 2 diabetes mellitus. Circulation. 2004;110:214–219
  45. Gerstein HC, Miller ME, Byington RP, et al. ACCORD (Action to Control Cardiovascular Risk in Diabetes) Study Group Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358:2545–2559
  46. Patel A, MacMahon S, Chalmers J, et al. ADVANCE Collaborative Group Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358:2560–2572
  47. Duckworth W, Abraira C, Moritz T, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2009;360:129–139
  48. Skyler JS, Bergenstal R, Bonow RO, et al. Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials (A position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association). Diabetes Care. 2009;32:187–192
  49. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359:1577–1589
  50. Buchanan TA. Pancreatic beta-cell loss and preservation in type 2 diabetes. Clin Ther. 2003;25(suppl B):B32–B46
  51. DeFronzo RA. Pathogenesis of type 2 diabetes mellitus. Med Clin North Am. 2004;88:787–835
  52. Kahn SE. The importance of β-cell failure in the development and progression of type 2 diabetes. J Clin Endocrinol Metab. 2001;86:4047–4058Clinical review 135
  53. Lebovitz HE. Insulin secretagogues: old and new. Diabetes Rev. 1999;7:139–153
  54. Del Prato S, Wishner WJ, Gromada J, Schluchter BJ. β-Cell mass plasticity in type 2 diabetes. Diabetes Obes Metab. 2004;6:319–331
  55. Weir GC, Laybutt DR, Kaneto H, Bonner-Weir S, Sharma A. β-Cell adaptation and decompensation during the progression of diabetes. Diabetes. 2001;50(suppl 1):S154–S159
  56. Garvey WT, Olefsky JM, Griffin J, Hamman RF, Kolterman OG. The effect of insulin treatment on insulin secretion and insulin action in type II diabetes mellitus. Diabetes. 1985;34:222–234

 Statement of author disclosure: Please see the Author Disclosures section at the end of this article.

PII: S0002-9343(09)01075-4

doi: 10.1016/j.amjmed.2009.12.004

The American Journal of Medicine
Volume 123, Issue 3, Supplement , Pages S3-S11 , March 2010

Article Tools

* Image Usage & Resolution